Advertisement

ADVERTISEMENT

novel treatments

ASCO Annual Meeting 2020
Conference Coverage
ASCO Annual Meeting 2020
05/27/2020
The ASCO 2020 Virtual Scientific Program (May 29-31) provided the opportunity to connect with oncology professionals around the world to explore and discuss cutting-edge research, therapies, and state-of-the-art...
The ASCO 2020 Virtual Scientific Program (May 29-31) provided the opportunity to connect with oncology professionals around the world to explore and discuss cutting-edge research, therapies, and state-of-the-art...
The...
05/27/2020
Journal of Clinical Pathways
Research in Review
Novel Prostate Cancer Biomarkers May Improve Targeted Therapy
08/15/2017
JCP Editors
Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts. Mutations within the SPOP gene are the most frequently documented genetic changes in...
Recent research has uncovered a new cause of treatment resistance in prostate cancer, which may improve targeted therapy efforts. Mutations within the SPOP gene are the most frequently documented genetic changes in...
Recent...
08/15/2017
Journal of Clinical Pathways
Research in Review
Double Dosage of ALK Inhibitor Improves Outcomes in NSCLC
08/09/2017
JCP Editors
Increasing the standard dose of an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of non-small cell lung cancer (NSCLC) improves objective response rates (ORR) by 9% with limited additional toxicity,...
Increasing the standard dose of an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of non-small cell lung cancer (NSCLC) improves objective response rates (ORR) by 9% with limited additional toxicity,...
...
08/09/2017
Journal of Clinical Pathways
Research in Review
Triplet Combination Shows Durable Responses in Advanced Multiple Myeloma
07/17/2017
JCP Editors
Patients with heavily treated multiple myeloma showed rapid and durable responses to a novel treatment combination, according to a recent study published in Blood (July 2017;...
Patients with heavily treated multiple myeloma showed rapid and durable responses to a novel treatment combination, according to a recent study published in Blood (July 2017;...
...
07/17/2017
Journal of Clinical Pathways
Research in Review
Immunotherapy Shows Promise in Rare Type of Lymphoma
07/11/2017
JCP Editors
A recent report demonstrates the promise of programmed death (PD-1) inhibition in improving outcomes for patients with a rare, difficult-to-treat type of lymphoma, published in The New England Journal of Medicine...
A recent report demonstrates the promise of programmed death (PD-1) inhibition in improving outcomes for patients with a rare, difficult-to-treat type of lymphoma, published in The New England Journal of Medicine...
A...
07/11/2017
Journal of Clinical Pathways
Research in Review
CAR-T Therapy Response Independent of Disease Factors in NHL
07/10/2017
JCP Editors
A recent clinical trial of a chimeric antigen receptor (CAR) T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive non-Hodgkin lymphoma (NHL) independent of disease...
A recent clinical trial of a chimeric antigen receptor (CAR) T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive non-Hodgkin lymphoma (NHL) independent of disease...
A...
07/10/2017
Journal of Clinical Pathways
Research in Review
Novel Prognostic Biomarker Identified in DLBCL
06/23/2017
JCP Editors
A new prognostic indicator involving monocytes has been identified for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to research presented at the 22nd Congress of the European...
A new prognostic indicator involving monocytes has been identified for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according to research presented at the 22nd Congress of the European...
A new...
06/23/2017
Journal of Clinical Pathways
Research in Review
Higher Dose Does Not Improve Efficacy of Gastric Cancer Treatment
06/20/2017
JCP Editors
A higher dose treatment for a type of metastatic gastric adenocarcinoma showed equivalent efficacy and safety, according to research published in the Journal of Clinical Oncology (published online June 2017;...
A higher dose treatment for a type of metastatic gastric adenocarcinoma showed equivalent efficacy and safety, according to research published in the Journal of Clinical Oncology (published online June 2017;...
A...
06/20/2017
Journal of Clinical Pathways
Research in Review
Earlier Endpoint May Be Predictive of Lung Cancer Therapy Outcomes
06/16/2017
JCP Editors
A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017;...
A novel intermediate endpoint could be a useful measure in clinical trials for metastatic non-small cell lung cancer (mNSCLC), according to a recent study published in JAMA (published online June 15, 2017;...
A...
06/16/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

March 23 ⁠–⁠ March 24
April 27 ⁠–⁠ April 28
Great Debates & Updates in Diabetic Foot
November 30 ⁠–⁠ December 2
AIBD logo
November 27 ⁠–⁠ November 29
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
May 13 ⁠–⁠ May 14
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use